### Supplement 2. Baseline characteristics of survivors who met inclusion criteria and were invited to participate in the study

<table>
<thead>
<tr>
<th>Variables</th>
<th>Study population</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males ($n = 195$)</td>
<td>Females ($n = 151$)</td>
<td>All ($n = 346$)</td>
<td></td>
</tr>
<tr>
<td><strong>Current age (years)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (min-max)</td>
<td>26 (18–39)</td>
<td>26 (18–39)</td>
<td>26 (18–39)</td>
<td></td>
</tr>
<tr>
<td><strong>Age (years) at cancer diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (min-max)</td>
<td>11 (1–17)</td>
<td>12 (1–18)</td>
<td>12 (1–18)</td>
<td></td>
</tr>
<tr>
<td><strong>Cancer type</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemias, myeloproliferative disorders, myelodysplasia n, (%)</td>
<td>92 (47.2)</td>
<td>73 (48.3)</td>
<td>165 (47.7)</td>
<td></td>
</tr>
<tr>
<td>Lymphomas and reticuloendothelial neoplasms n, (%)</td>
<td>71 (36.4)</td>
<td>51 (33.8)</td>
<td>122 (35.3)</td>
<td></td>
</tr>
<tr>
<td>Central Nervous System tumors n, (%)</td>
<td>2 (1)</td>
<td>0</td>
<td>2 (0.6)</td>
<td></td>
</tr>
<tr>
<td>Neuroblastoma and other peripheral nerve sheath tumors n, (%)</td>
<td>1 (0.5)</td>
<td>4 (2.6)</td>
<td>5 (1.4)</td>
<td></td>
</tr>
<tr>
<td>Nephroblastoma and other kidney malignancies n, (%)</td>
<td>4 (2.1)</td>
<td>8 (5.3)</td>
<td>12 (3.5)</td>
<td></td>
</tr>
<tr>
<td>Liver malignancies n, (%)</td>
<td>0</td>
<td>1 (0.7)</td>
<td>1 (0.3)</td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma and other bone malignancies n, (%)</td>
<td>9 (4.6)</td>
<td>9 (6.0)</td>
<td>18 (5.2)</td>
<td></td>
</tr>
<tr>
<td>Soft-tissue sarcoma n, (%)</td>
<td>9 (4.6)</td>
<td>2 (1.3)</td>
<td>11 (3.2)</td>
<td></td>
</tr>
<tr>
<td>Germinative, trophoblastic, and gonadal tumors n, (%)</td>
<td>5 (2.6)</td>
<td>0</td>
<td>5 (1.4)</td>
<td></td>
</tr>
<tr>
<td>Other epithelial tumors and melanoma n, (%)</td>
<td>1 (0.5)</td>
<td>2 (1.3)</td>
<td>3 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Other tumors n, (%)</td>
<td>1 (0.5)</td>
<td>1 (0.7)</td>
<td>2 (0.6)</td>
<td></td>
</tr>
</tbody>
</table>

*according to ICCC-3 (International classification of childhood cancer)